Your travel kit stays simpler, and you eliminate the stress of injecting in hotel rooms or airport bathrooms
Some prescribers do use all three together, but this requires particularly careful monitoring
Between 40-82% of people experience gastrointestinal symptoms
Wegovy conducted a study with 1,900 adults who were obese or overweight with comorbidity (high blood pressure or high cholesterol) and found that people lost a median of 15% of their weight while on a target weight loss dose of medication (2.4 mg/week)
These events were generally mild to moderate in severity and included: Nausea often accompanying changes in bowel habits, particularly after dose escalation Diarrhoea loose or watery stools, sometimes with urgency Vomiting less common but reported, especially at higher doses Constipation occurring in some individuals, reflecting the variable effect on gut motility Abdominal discomfort or bloating a sensation of fullness or cramping Flatulence increased wind, which can accompany altered digestion Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 510% of participants depending on dose group